Cardiovascular Diseases

Bayer Partners with DelSiTech to Develop Innovative Drug Delivery Technology for Ophthalmology Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology Licence Agreement. The agreement gives Bayer’s compounds a worldwide application of DelSiTech’s Silica Matrix drug delivery platform, especially in ophthalmology. DelSiTech is entitled to receive a number of undisclosed milestone payments triggered by the successful completion of different stages of development, and Bayer will fund all developmental and commercialization costs of the collaborative projects. Amgen and Arrowhead Pharmaceuticals ...